Biotechnology · Hayward, California, United States
$13.48
+0.60% (+$0.08)2026-07-08
Smart-Money SignalNeutral · 50/100— Insider open-market flow is flat over 90 days
Revenue$0
Net Income-$11.9M
EPS$-0.72
Market Cap$463.1M
Price Performance
Historical data including institutional events
Company Profile
J
Jerel Banks
CEO & Executive Director
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia.
Benitec Biopharma Inc. is headquartered in Hayward, California.
